What is Amgen Inc. share price today?

Amgen Inc. (AMGN) share price today is {{live_price}}.

Can Indians buy Amgen Inc. shares?

Yes, Indians can invest in the Amgen Inc. (AMGN) from India. With INDmoney, you can buy Amgen Inc. at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Amgen Inc. at zero transaction cost.

How can I buy Amgen Inc. shares from India?

It is very easy to buy Amgen Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amgen Inc. be purchased?

Yes, you can buy fractional shares of Amgen Inc. with INDmoney app.

What are the documents required to start investing in Amgen Inc. stocks?

To start investing in Amgen Inc., You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Amgen Inc.

Today’s highest price of Amgen Inc. (AMGN) is {{1_rba_end}}. Today’s lowest price of Amgen Inc. (AMGN) is {{1_rba_st}}.

What is today's market capitalisation of Amgen Inc.

Today's market capitalisation of Amgen Inc. AMGN is 172.7B

What is the 52 Week High and Low Range of Amgen Inc.

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Amgen Inc. is down from its 52 Week High?

Amgen Inc. (AMGN) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Amgen Inc. is up from its 52 Week low?

Amgen Inc. (AMGN) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Amgen Inc.?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Amgen Inc.

Mr. Robert A. Bradway is the current Chief Executive Officer (CEO) of Amgen Inc..

Home>
US Stocks>
Amgen Inc.

Amgen Inc. (AMGN)

$317.68

-3.98

(-1.24%)▲

Live

Amgen, Inc. is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Performance

$315.87
$321.77
$317.68
0.57%
Downside
Day's Volatility :1.83%
Upside
1.27%
$249.70
$346.85
$317.68
21.4%
Downside
52 Weeks Volatility :28.01%
Upside
8.41%

Returns

Period	Amgen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-4.26%	3.6%	4.3%
6 Months	18.3%	10.2%	21.0%
1 Year	17.8%	19.6%	42.4%
3 Years	53.91%	16.8%	21.5%

Highlights

Market Capitalization	172.7B
Book Value	$11.03
Dividend Share	8.76
Dividend Yield	2.8%
Earnings Per Share (EPS)	5.79
PE Ratio	55.5
PEG Ratio	2.24
Wall Street Target Price	332.2

Profit Margin	10.12%
Operating Margin TTM	22.91%

Return On Assets TTM	4.48%
Return On Equity TTM	49.27%

Revenue TTM	30.9B
Revenue Per Share TTM	57.66
Quarterly Revenue Growth YOY	20.1%
Gross Profit TTM	19.9B
EBITDA	11.6B
Diluted Eps TTM	5.79
Quarterly Earnings Growth YOY	-0.46

EPS Estimate Current Year	19.49
EPS Estimate Next Year	20.63
EPS Estimate Current Quarter	5.01
EPS Estimate Next Quarter	5.15

Analyst Recommendation

Buy

56%Buy

35%Hold

8%Sell

Based on 37 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)

Based on 37 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 4.57%

Current $317.68

Target $332.20

Company Financials

	FY18	Y/Y Change
Revenue	23.7B	↑ 3.93%
Net Income	8.4B	↑ 324.15%
Net Profit Margin	35.35%	↑ 26.69%

	FY19	Y/Y Change
Revenue	23.4B	↓ 1.62%
Net Income	7.8B	↓ 6.58%
Net Profit Margin	33.57%	↓ 1.78%

	FY20	Y/Y Change
Revenue	25.4B	↑ 8.83%
Net Income	7.3B	↓ 7.37%
Net Profit Margin	28.57%	↓ 5.0%

	FY21	Y/Y Change
Revenue	26.0B	↑ 2.18%
Net Income	5.9B	↓ 18.87%
Net Profit Margin	22.68%	↓ 5.89%

	FY22	Y/Y Change
Revenue	26.3B	↑ 1.32%
Net Income	6.6B	↑ 11.18%
Net Profit Margin	24.89%	↑ 2.21%

	FY23	Y/Y Change
Revenue	28.2B	↑ 7.09%
Net Income	6.7B	↑ 2.52%
Net Profit Margin	23.83%	↓ 1.06%

	Q1 FY23	Q/Q Change
Revenue	6.1B	↓ 10.73%
Net Income	2.8B	↑ 75.8%
Net Profit Margin	46.54%	↑ 22.91%

	Q2 FY23	Q/Q Change
Revenue	7.0B	↑ 14.43%
Net Income	1.4B	↓ 51.46%
Net Profit Margin	19.74%	↓ 26.8%

	Q3 FY23	Q/Q Change
Revenue	6.9B	↓ 1.19%
Net Income	1.7B	↑ 25.45%
Net Profit Margin	25.06%	↑ 5.32%

	Q4 FY23	Q/Q Change
Revenue	8.2B	↑ 18.73%
Net Income	767.0M	↓ 55.66%
Net Profit Margin	9.36%	↓ 15.7%

	Q1 FY24	Q/Q Change
Revenue	7.4B	↓ 9.76%
Net Income	-113.0M	↓ 114.73%
Net Profit Margin	-1.53%	↓ 10.89%

	Q2 FY24	Q/Q Change
Revenue	8.3B	↑ 12.67%
Net Income	746.0M	↓ 760.18%
Net Profit Margin	8.95%	↑ 10.48%

	FY18	Y/Y Change
Total Assets	66.4B	↓ 16.93%
Total Liabilities	53.9B	↓ 1.46%

	FY19	Y/Y Change
Total Assets	59.7B	↓ 10.1%
Total Liabilities	50.0B	↓ 7.2%

	FY20	Y/Y Change
Total Assets	62.9B	↑ 5.43%
Total Liabilities	53.5B	↑ 7.01%

	FY21	Y/Y Change
Total Assets	61.2B	↓ 2.83%
Total Liabilities	54.5B	↑ 1.73%

	FY22	Y/Y Change
Total Assets	65.1B	↑ 6.47%
Total Liabilities	61.5B	↑ 12.84%

	FY23	Y/Y Change
Total Assets	97.2B	↑ 49.19%
Total Liabilities	90.9B	↑ 47.94%

	Q1 FY23	Q/Q Change
Total Assets	88.7B	↑ 36.24%
Total Liabilities	83.4B	↑ 35.65%

	Q2 FY23	Q/Q Change
Total Assets	90.3B	↑ 1.75%
Total Liabilities	83.5B	↑ 0.14%

	Q3 FY23	Q/Q Change
Total Assets	90.5B	↑ 0.29%
Total Liabilities	82.9B	↓ 0.73%

	Q4 FY23	Q/Q Change
Total Assets	97.2B	↑ 7.31%
Total Liabilities	90.9B	↑ 9.71%

	Q1 FY24	Q/Q Change
Total Assets	93.0B	↓ 4.3%
Total Liabilities	88.0B	↓ 3.26%

	Q2 FY24	Q/Q Change
Total Assets	90.9B	↓ 2.23%
Total Liabilities	85.0B	↓ 3.38%

	FY18	Y/Y Change
Operating Cash Flow	11.3B	↑ 1.06%
Investing Cash Flow	14.3B	↓ 456.34%
Financing Cash Flow	-22.5B	↑ 241.07%

	FY19	Y/Y Change
Operating Cash Flow	9.2B	↓ 19.0%
Investing Cash Flow	5.7B	↓ 60.19%
Financing Cash Flow	-15.8B	↓ 29.89%

	FY20	Y/Y Change
Operating Cash Flow	10.5B	↑ 14.72%
Investing Cash Flow	-5.4B	↓ 194.61%
Financing Cash Flow	-4.9B	↓ 69.13%

	FY21	Y/Y Change
Operating Cash Flow	9.3B	↓ 11.77%
Investing Cash Flow	733.0M	↓ 113.57%
Financing Cash Flow	-8.3B	↑ 69.94%

	FY22	Y/Y Change
Operating Cash Flow	9.7B	↑ 4.97%
Investing Cash Flow	-6.0B	↓ 924.56%
Financing Cash Flow	-4.0B	↓ 51.19%

	FY23	Y/Y Change
Operating Cash Flow	8.5B	↓ 12.86%
Investing Cash Flow	-26.2B	↑ 333.55%
Financing Cash Flow	21.0B	↓ 621.38%

	Q1 FY23	Q/Q Change
Operating Cash Flow	1.1B	↓ 59.83%
Investing Cash Flow	1.4B	↓ 139.1%
Financing Cash Flow	21.5B	↓ 2150.43%

	Q2 FY23	Q/Q Change
Operating Cash Flow	4.1B	↑ 286.18%
Investing Cash Flow	-211.0M	↓ 115.54%
Financing Cash Flow	-1.2B	↓ 105.63%

	Q3 FY23	Q/Q Change
Operating Cash Flow	2.8B	↓ 32.83%
Investing Cash Flow	-262.0M	↑ 24.17%
Financing Cash Flow	-2.0B	↑ 65.7%

	Q4 FY23	Q/Q Change
Operating Cash Flow	538.0M	↓ 80.51%
Investing Cash Flow	-27.1B	↑ 10239.31%
Financing Cash Flow	2.8B	↓ 237.36%

	Q1 FY24	Q/Q Change
Operating Cash Flow	689.0M	↑ 28.07%
Investing Cash Flow	-217.0M	↓ 99.2%
Financing Cash Flow	-1.7B	↓ 162.02%

Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amgen Inc.	-4.16%	18.3%	17.8%	53.91%	58.51%
Eli Lilly And Company	-0.06%	25.52%	59.19%	280.63%	750.68%
Johnson & Johnson	1.16%	10.73%	9.07%	1.05%	28.98%
Merck & Co. Inc.	-5.99%	-14.37%	5.18%	33.92%	28.61%
Abbvie Inc	-2.56%	12.49%	30.49%	73.65%	144.32%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amgen Inc.	55.5	55.5	2.24	19.49	0.49	0.04	0.03	11.03
Eli Lilly And Company	112.5	112.5	0.87	13.38	0.59	0.14	0.01	15.06
Johnson & Johnson	27.19	27.19	0.96	9.93	0.22	0.08	0.03	29.72
Merck & Co. Inc.	20.32	20.32	0.08	7.9	0.33	0.11	0.03	17.19
Abbvie Inc	63.07	63.07	0.45	10.87	0.54	0.08	0.03	3.84

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amgen Inc.	Buy	$172.7B	58.51%	55.5	10.12%
Eli Lilly And Company	Buy	$826.6B	750.68%	112.5	18.86%
Johnson & Johnson	Buy	$395.9B	28.98%	27.19	16.74%
Merck & Co. Inc.	Buy	$278.2B	28.61%	20.32	21.99%
Abbvie Inc	Buy	$333.1B	144.32%	63.07	9.71%

Insights on Amgen Inc.

Increasing Revenue
Revenue is up for the last 2 quarters, 7.39B → 8.33B (in $), with an average increase of 11.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -113.0M → 746.0M (in $), with an average increase of 115.2% per quarter
Vs LLY
In the last 1 year, Eli Lilly And Company has given 57.0% return, outperforming this stock by 41.6%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 280.6% return, outperforming this stock by 226.7%

Institutional Holdings

Vanguard Group Inc
9.65%
BlackRock Inc
8.57%
State Street Corp
5.39%
PRIMECAP Management Company
2.69%
Morgan Stanley - Brokerage Accounts
2.67%
Geode Capital Management, LLC
2.24%

Corporate Announcements

Amgen Inc. Dividends March,2024
In the quarter ending March,2024. Amgen Inc. has declared dividend of $2.25
Read More

Organization	Amgen Inc.
Employees	26700
CEO	Mr. Robert A. Bradway
Industry	Health Technology

Amgen Inc. (AMGN)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Increasing Revenue

Increasing Net Profit

Vs LLY

Vs LLY

Institutional Holdings

Corporate Announcements

Amgen Inc. Dividends March,2024

Company Information

Discover More

FAQs